New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSyn-Coll vs Eloralintide

Syn-Coll vs Eloralintide

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
Syn-Coll
GLP-1 / Weight Loss Agonists
Eloralintide
Summary
Syn-Coll is a palmitoylated tripeptide (Palmitoyl Tripeptide-5) that mimics thrombospondin-1 to activate TGF-beta, the primary growth factor driving collagen synthesis in the dermis. It is one of the most mechanistically direct collagen-stimulating peptides in cosmetic formulations.
Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
Half-Life
Extended (lipid depot in stratum corneum)
~7 days (estimated, long-acting design)
Admin Route
Topical
SubQ
Research
Typical Dose
0.005-0.05% in formulation
Under investigation in Phase 1/2 trials
Frequency
Once or twice daily
Once weekly
Key Benefits
  • Directly activates TGF-beta for potent collagen synthesis stimulation
  • Increases dermal thickness and firmness
  • Reduces depth of wrinkles and fine lines
  • Improves skin elasticity
  • Clinically validated in collagen induction studies
  • Complementary to retinoids or vitamin C
  • Once-weekly dosing (vs multiple daily injections for pramlintide)
  • Appetite suppression via central amylin receptor activation
  • Reduction in post-meal glucagon secretion
  • Complementary mechanism to GLP-1 agonists for combination therapy
  • Slows gastric emptying for prolonged satiety
  • Potential additive weight loss when combined with GLP-1 agents
Side Effects
  • Generally well-tolerated
  • Rare mild irritation at high concentrations
  • Possible sensitivity in individuals with inflammatory skin conditions
  • Nausea
  • Vomiting
  • Decreased appetite
  • Injection site reactions
  • +1 more
Stacks With